Novel Formulation Innovation and Advanced Technology Capability in Pulmonary Drug Delivery: The Mediating Role of Delivery Performance and the Moderating Role of Regulatory Support in Commercialisation Implementation Success
Main Article Content
Abstract
This study considers the innovation of novel formulations (NFI), advanced technologies (ATC), and their integration with other processes to achieve competitive advantage in the domain of pulmonary drug delivery performance (PDDP). It explores the association of PDDP with commercialisation implementation success (CIS) and the role of regulatory support (RS) in moderating the relationship of PDDP with CIS. It also examines the role of PDDP in the association of NFI and CIS, as well as ATC and CIS. A total of 326 completed workbooks were audited for two separate data sets. For each workbook, mean scores were computed for “four item responses for each of the five constructs, as well as an interaction term for centered PDDP and RS. The means for the corrected data set were 3.436, 3.466, 3.519, 3.495, and 3.499, respectively, for NFI, ATC, PDDP, CIS, and RS, respectively. The five blocks made up of four items had poor internal consistency (alpha = −.193 to .164). Using HC3-adjusted regressions, the relationships of NFI and ATC to PDDP (R² = .003) and the relationship of PDDP to CIS with NFI, ATC (R² = .001) were also estimated. The interaction of PDDP and RS was also estimated (B = −.045; p = .607). Based on these results, the research hypotheses, and the adjustments made to the regression models, it can be inferred that the research hypotheses were not supported, while the mediation hypotheses could not be evaluated. It is important to mention that the results of this research did not support the research hypotheses; rather the current measures did not provide sufficient evidence to accept the research hypotheses.
